UK Approves Sale of Promising Smoking Cessation Medication, Cytisine

Business by 2FIRSTS.ai
Jan.03.2024
UK Approves Sale of Promising Smoking Cessation Medication, Cytisine
UK approves sale of Cytisine, a smoking cessation drug with potential to significantly help smokers quit, reports The Guardian.

According to a report by The Guardian on January 2nd, the UK has approved the sale of a smoking cessation drug called Cytisine, which could play a significant role in helping people quit smoking.

 

Even though many smokers have turned to nicotine alternative products that are safer than cigarettes, doctors have discovered a drug called cytisine (a natural ingredient found in the seeds of the golden chain tree) that can help smokers quit their addiction, with a success rate of more than double. This drug has been in use in Central and Eastern Europe for decades but is not available in most countries, including the United States. Recently, it gained approval from regulatory authorities in the United Kingdom and is expected to hit the market at the end of this month.

 

Argentinian researchers conducted a thorough analysis of 12 randomized controlled trials comparing the success rates of smokers using Cytisine, a placebo, another smoking cessation drug called Champix, or nicotine replacement therapies such as patches or nicotine pouches.

 

Researchers have discovered that Cytisine, a plant alkaloid, is more than twice as effective as a placebo. Several studies under review indicate that this medication has similarities to Varenicline and might be more effective than nicotine replacement therapy.

 

According to Argentine toxicologist Omar, "Smoking is considered a major preventable cause of death worldwide. Nicotine may become one of the important solutions to address this issue."

 

The alkaloid vincamine will be available on the market in the UK as a prescription drug by the end of January. However, the cost of a 25-day treatment with 100 pills is £115, which may hinder certain regions from including this medication as part of their healthcare services for the public.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Huabao International Buys Indonesian HNB Manufacturer for RMB 90 Million, Adding OEM/ODM Capacity
Huabao International Buys Indonesian HNB Manufacturer for RMB 90 Million, Adding OEM/ODM Capacity
Huabao International Holdings Limited will acquire 100% of PT Broad Far Indonesia through two wholly owned subsidiaries for approximately RMB 90 million. The Indonesian company manufactures and sells heat-not-burn tobacco sticks and provides OEM/ODM services. The sellers are part of a related-party group controlled by Huabao International Chair and controlling shareholder Zhu Linyao. PT Broad Far Indonesia generated $4.37 million in revenue and $177,000 in profit after tax in the first half of 2026, while net assets stood at about $326,000 at June-end. An independent valuer assessed the company’s equity at approximately RMB 93.06 million. Following completion, the HNB manufacturing operation will be consolidated into Huabao International.
News
Sep.29 by 2Firsts Perspectives
Philip Morris Loses Two European Nicotine Pouch Patents in a Month Following BAT Challenges Over Nicotine Release and Formulation Technology
Philip Morris Loses Two European Nicotine Pouch Patents in a Month Following BAT Challenges Over Nicotine Release and Formulation Technology
The European Patent Office (EPO) published an appeal decision on November 17, 2026, revoking Philip Morris Products S.A.'s European nicotine pouch patent EP 3773494, covering a formulation involving free-base nicotine, ion-exchange resin and a water content of at least 15%. The decision followed an opposition and appeal brought by British American Tobacco (BAT) entity Nicoventures Trading Limited. Philip Morris withdrew its approval of the patent text during the appeal, leading the EPO to revoke the patent. A separate European patent, EP 3809884, covering the distribution of nicotine between a pouch membrane and its internal composition, had been revoked on September 24 following a challenge from another BAT entity. The patents share a 2019 priority basis, while related European divisional applications also exist.
company
Nov.18 by 2Firsts Perspectives
FDA Authorizes 24 VELO Nicotine Pouches, Increasing U.S. Authorized Total by 56%
FDA Authorizes 24 VELO Nicotine Pouches, Increasing U.S. Authorized Total by 56%
The U.S. FDA authorized 24 VELO nicotine pouch products from a British American Tobacco subsidiary, raising the total number of authorized products from 43 to 67, a 55.8% increase. The newly authorized 4 mg products include lime and passion fruit flavors and feature certified child-resistant packaging. VELO's first FDA marketing authorization adds BAT to a list previously limited to PMI and Altria products, while bringing the agency's nicotine pouch review pilot total to 47 authorized products.
Oct.30
Spain Cigarette Volumes Fall 5.2% in August, BAT Drops 14.5%, JTI Gains Share; France Down 8.3% on Adjusted Basis
Spain Cigarette Volumes Fall 5.2% in August, BAT Drops 14.5%, JTI Gains Share; France Down 8.3% on Adjusted Basis
Spain's cigarette volumes declined 5.2% year over year in August 2026, according to government data cited by UBS and reported by Investing.com on October 7. British American Tobacco's volumes fell 14.5%, followed by Imperial Brands at 8.8%, Philip Morris International at 6.6% and Japan Tobacco at 4.6%. JTI was the only one of the four companies to gain cigarette market share, rising six basis points to 26.7%. In France, official customs data showed an unadjusted 3.7% decline in cigarette deliveries. Adjusting for the difference in delivery days produces a decline of approximately 8.3%, consistent with the UBS figure. The bank also estimated the earnings exposure of major tobacco companies to both markets.
Market
Oct.13
Pennsylvania Vape Directory Enforcement Starts Oct. 19, Barring Retail Sales of Unlisted Products
Pennsylvania Vape Directory Enforcement Starts Oct. 19, Barring Retail Sales of Unlisted Products
Pennsylvania's Act 57 vape directory regime will reach the end of its 120-day inventory transition period on Oct. 19. Nicotine-containing e-cigarettes intended for retail sale in the state that are not listed on the Attorney General's ENDS directory will then be barred from retail sale and treated as contraband subject to seizure, forfeiture and destruction. Manufacturers face annual product certification, brand- and style-based fees and a minimum $50,000 surety bond, while retailers and wholesalers must source through licensed channels and monitor the directory.
Regulations
Oct.08
Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia's Therapeutic Goods Administration published a final decision on September 25 to classify 6-methylnicotine as a Schedule 9 prohibited substance under the Poisons Standard, effective October 1, 2026. TGA said the chemical has been reported in e-cigarette liquids sold in Australia and marketed as nicotine-free or nicotine alternatives, while evidence also indicates its use in preparations such as oral pouches. The government originally proposed a Schedule 7 classification but ultimately adopted the stricter Schedule 9 designation, citing acute toxicity, dependence risk, use in unapproved consumer products and misleading marketing.
News
Sep.29 by 2Firsts Perspectives